| scholarly article | Q13442814 |
| P50 | author | Yair Lotan | Q61862568 |
| P2093 | author name string | Ryan Hutchinson | |
| P2860 | cites work | Systematic review of complications of prostate biopsy | Q26822966 |
| Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology | Q27008215 | ||
| Multiparametric ultrasound in the detection of prostate cancer: a systematic review | Q28086868 | ||
| Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort | Q29037865 | ||
| PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 | Q29037908 | ||
| Screening and prostate-cancer mortality in a randomized European study | Q29617485 | ||
| Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies | Q33557377 | ||
| Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology | Q33590993 | ||
| Early detection of prostate cancer: AUA Guideline | Q33608474 | ||
| The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. | Q33617669 | ||
| Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending | Q33652793 | ||
| Mortality results from the Göteborg randomised population-based prostate-cancer screening trial | Q33873969 | ||
| Prostate MRI: access to and current practice of prostate MRI in the United States | Q34217791 | ||
| Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement | Q34288506 | ||
| Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment | Q34475350 | ||
| Projections of the cost of cancer care in the United States: 2010-2020. | Q35022830 | ||
| The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review | Q35735296 | ||
| Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit? | Q35838209 | ||
| Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study | Q35955315 | ||
| Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? | Q36018610 | ||
| The cost implications of prostate cancer screening in the Medicare population. | Q37402386 | ||
| Consideration of comorbidity in risk stratification prior to prostate biopsy | Q37415134 | ||
| Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer | Q37457676 | ||
| Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review | Q38022388 | ||
| Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis | Q38060064 | ||
| The economics of active surveillance for prostate cancer | Q38085518 | ||
| Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study | Q38098361 | ||
| Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection | Q38183902 | ||
| Multiparametric magnetic resonance imaging of the prostate: technical aspects and role in clinical management | Q38237541 | ||
| Multiparametric MRI-targeted TRUS prostate biopsies using visual registration | Q38294506 | ||
| Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. | Q38410592 | ||
| Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial? | Q38414241 | ||
| Novel biomarkers and genomic tests in prostate cancer: a critical analysis. | Q38520713 | ||
| PI-RADS version 2: what you need to know | Q38558548 | ||
| The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis | Q38685451 | ||
| National health expenditure projections, 2014-24: spending growth faster than recent trends | Q38980047 | ||
| A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session | Q39665323 | ||
| Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower | Q39722492 | ||
| Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen | Q40062114 | ||
| PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study | Q40092879 | ||
| Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies | Q40209282 | ||
| In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? | Q40224363 | ||
| The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA i | Q40267154 | ||
| Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment | Q40281409 | ||
| The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years | Q40734494 | ||
| Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance | Q40832222 | ||
| Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy | Q41651733 | ||
| Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. | Q42602506 | ||
| Management of MRI wait lists in Canada | Q43165620 | ||
| A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial | Q43493324 | ||
| Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer | Q44199886 | ||
| Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. | Q45967722 | ||
| Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis | Q46312236 | ||
| Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. | Q46326701 | ||
| Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis | Q46745028 | ||
| Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy | Q47106965 | ||
| Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? | Q47780788 | ||
| Reevaluating PSA Testing Rates in the PLCO Trial | Q48536606 | ||
| Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. | Q50908926 | ||
| Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. | Q50991046 | ||
| T2- and diffusion-weighted magnetic resonance imaging at 3T for the detection of prostate cancer with and without endorectal coil: An intraindividual comparison of image quality and diagnostic performance. | Q52852580 | ||
| MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. | Q52936107 | ||
| Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. | Q53304507 | ||
| Treatment patterns for older veterans with localized prostate cancer. | Q53400113 | ||
| Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. | Q53579358 | ||
| Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound–Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies | Q56688802 | ||
| Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis | Q57253236 | ||
| Targeted Antimicrobial Prophylaxis Using Rectal Swab Cultures in Men Undergoing Transrectal Ultrasound Guided Prostate Biopsy is Associated With Reduced Incidence of Postoperative Infectious Complications and Cost of Care | Q57779706 | ||
| A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population | Q87299887 | ||
| Poor standard mp-MRI and routine biopsy fail to precisely predict intraprostatic tumor localization | Q87349673 | ||
| Is prostate magnetic resonance imaging going to break the bank? | Q87419512 | ||
| How to Code for Magnetic Resonance Imaging-informed Prostate Biopsies | Q93607855 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 345-354 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Translational andrology and urology | Q27724139 |
| P1476 | title | Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer | |
| P478 | volume | 6 |
| Q89362595 | Author Reply |
| Q87942292 | Cost and cost-effectiveness studies in urologic oncology using large administrative databases |
| Q92397846 | Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort |
| Q92744935 | Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer |
| Q98298548 | Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice |
Search more.